The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase 1 – 10187
A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients with Metastatic Clear Cell Renal Cell Carcinoma
National Heart Lung and Blood Institute
Childs, Richard W.
(301) 451-7128
Phase II – EA9171
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ECOG-ACRIN Cancer Research Group
Zeidan, Amer M.
(203) 737-2572
Phase II – NRG-GU006
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
NRG Oncology
Feng, Felix Yi-Chung
(415) 353-7183
Phase III – CCTG MA.39
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Canadian Cancer Trials Group
Whelan, Timothy Joseph
(905) 387-9711
Phase Other – ANBL17B5-Q
Growth Factor Receptor Trafficking and Neuroblastoma Differentiation
Children’s Oncology Group
Zage, Peter Eric
(858) 534-6494
